{"entity":{"type":"insider","cik":"0001654337","url":"/insider/0001654337","json_url":"/insider/0001654337.json","name":"Ali-Jackson Kamil","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":26,"n_filings":12,"first":"2016-08-29","last":"2026-06-24","span_basis":"filed_date"},"name_variants":[{"name":"Ali-Jackson Kamil","source":"filing","n_filings":12,"first_seen":"2016-08-29","last_seen":"2026-06-24"}],"transactions":[{"id":5804986,"accession":"0000905148-26-003076","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-26-003076","line_url":"/filing/0000905148-26-003076#line-1","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":87500.0,"total_display":"87,500.00","total_whole":"87,500","shares_owned_after":10125.0,"shares_owned_after_display":"10,125","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-22","filed_date":"2026-06-24","scope":"insider"},{"id":6069697,"accession":"0000905148-26-002724","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-26-002724","line_url":"/filing/0000905148-26-002724#line-1","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":29.17,"price_display":"29.17","price_state":"stated","total_value":72925.0,"total_display":"72,925.00","total_whole":"72,925","shares_owned_after":12625.0,"shares_owned_after_display":"12,625","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-26","filed_date":"2026-05-28","scope":"insider"},{"id":5006658,"accession":"0001140361-21-021497","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-21-021497","line_url":"/filing/0001140361-21-021497#line-1","is_derivative":false,"issuer_cik":"0001472091","issuer_name":"PDS Biotechnology Corp","issuer_ticker":"PDSB","issuer_name_source":null,"issuer_url":"/issuer/0001472091","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11764.0,"shares_display":"11,764","price_per_share":8.5,"price_display":"8.50","price_state":"stated","total_value":99994.0,"total_display":"99,994.00","total_whole":"99,994","shares_owned_after":11764.0,"shares_owned_after_display":"11,764","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-17","scope":"insider"},{"id":5100790,"accession":"0001209191-21-038442","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-038442","line_url":"/filing/0001209191-21-038442#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9492.0,"shares_display":"9,492","price_per_share":21.9575,"price_display":"21.96","price_state":"stated","total_value":208420.59,"total_display":"208,420.59","total_whole":"208,421","shares_owned_after":122196.0,"shares_owned_after_display":"122,196","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-03","filed_date":"2021-06-04","scope":"insider"},{"id":4837357,"accession":"0001209191-21-037482","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-037482","line_url":"/filing/0001209191-21-037482#line-7","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12732.0,"shares_display":"12,732","price_per_share":21.5066,"price_display":"21.51","price_state":"stated","total_value":273822.0312,"total_display":"273,822.03","total_whole":"273,822","shares_owned_after":134075.0,"shares_owned_after_display":"134,075","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-02","scope":"insider"},{"id":4837352,"accession":"0001209191-21-037482","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-037482","line_url":"/filing/0001209191-21-037482#line-6","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12483.0,"shares_display":"12,483","price_per_share":21.5022,"price_display":"21.50","price_state":"stated","total_value":268411.9626,"total_display":"268,411.96","total_whole":"268,412","shares_owned_after":149324.0,"shares_owned_after_display":"149,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-02","scope":"insider"},{"id":4837348,"accession":"0001209191-21-037482","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-037482","line_url":"/filing/0001209191-21-037482#line-5","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2517.0,"shares_display":"2,517","price_per_share":22.3175,"price_display":"22.32","price_state":"stated","total_value":56173.1475,"total_display":"56,173.15","total_whole":"56,173","shares_owned_after":146807.0,"shares_owned_after_display":"146,807","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-02","scope":"insider"},{"id":4837343,"accession":"0001209191-21-037482","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-037482","line_url":"/filing/0001209191-21-037482#line-4","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2387.0,"shares_display":"2,387","price_per_share":22.3112,"price_display":"22.31","price_state":"stated","total_value":53256.8344,"total_display":"53,256.83","total_whole":"53,257","shares_owned_after":131688.0,"shares_owned_after_display":"131,688","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-02","scope":"insider"},{"id":4837337,"accession":"0001209191-21-037482","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-037482","line_url":"/filing/0001209191-21-037482#line-3","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9746.0,"shares_display":"9,746","price_per_share":22.7219,"price_display":"22.72","price_state":"stated","total_value":221447.6374,"total_display":"221,447.64","total_whole":"221,448","shares_owned_after":167061.0,"shares_owned_after_display":"167,061","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-02","scope":"insider"},{"id":4837332,"accession":"0001209191-21-037482","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-037482","line_url":"/filing/0001209191-21-037482#line-2","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5254.0,"shares_display":"5,254","price_per_share":23.5728,"price_display":"23.57","price_state":"stated","total_value":123851.4912,"total_display":"123,851.49","total_whole":"123,851","shares_owned_after":161807.0,"shares_owned_after_display":"161,807","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-02","scope":"insider"},{"id":4997060,"accession":"0001209191-21-031038","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-031038","line_url":"/filing/0001209191-21-031038#line-6","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3316.0,"shares_display":"3,316","price_per_share":23.2255,"price_display":"23.23","price_state":"stated","total_value":77015.758,"total_display":"77,015.76","total_whole":"77,016","shares_owned_after":145718.0,"shares_owned_after_display":"145,718","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-07","filed_date":"2021-05-07","scope":"insider"},{"id":4997057,"accession":"0001209191-21-031038","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-031038","line_url":"/filing/0001209191-21-031038#line-5","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2100.0,"shares_display":"2,100","price_per_share":23.9886,"price_display":"23.99","price_state":"stated","total_value":50376.06,"total_display":"50,376.06","total_whole":"50,376","shares_owned_after":143618.0,"shares_owned_after_display":"143,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-07","filed_date":"2021-05-07","scope":"insider"},{"id":4997050,"accession":"0001209191-21-031038","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-031038","line_url":"/filing/0001209191-21-031038#line-3","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11898.0,"shares_display":"11,898","price_per_share":23.318,"price_display":"23.32","price_state":"stated","total_value":277437.564,"total_display":"277,437.56","total_whole":"277,438","shares_owned_after":146720.0,"shares_owned_after_display":"146,720","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-06","filed_date":"2021-05-07","scope":"insider"},{"id":4997046,"accession":"0001209191-21-031038","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-031038","line_url":"/filing/0001209191-21-031038#line-2","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3102.0,"shares_display":"3,102","price_per_share":23.8606,"price_display":"23.86","price_state":"stated","total_value":74015.5812,"total_display":"74,015.58","total_whole":"74,016","shares_owned_after":143618.0,"shares_owned_after_display":"143,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-06","filed_date":"2021-05-07","scope":"insider"},{"id":4892346,"accession":"0001209191-21-030491","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-21-030491","line_url":"/filing/0001209191-21-030491#line-9","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14502.0,"shares_display":"14,502","price_per_share":23.968,"price_display":"23.97","price_state":"stated","total_value":347583.936,"total_display":"347,583.94","total_whole":"347,584","shares_owned_after":144116.0,"shares_owned_after_display":"144,116","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-05","filed_date":"2021-05-05","scope":"insider"},{"id":4892342,"accession":"0001209191-21-030491","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-030491","line_url":"/filing/0001209191-21-030491#line-8","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":498.0,"shares_display":"498","price_per_share":24.3559,"price_display":"24.36","price_state":"stated","total_value":12129.2382,"total_display":"12,129.24","total_whole":"12,129","shares_owned_after":143618.0,"shares_owned_after_display":"143,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-05","filed_date":"2021-05-05","scope":"insider"},{"id":4892335,"accession":"0001209191-21-030491","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-030491","line_url":"/filing/0001209191-21-030491#line-6","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13721.0,"shares_display":"13,721","price_per_share":23.6055,"price_display":"23.61","price_state":"stated","total_value":323891.0655,"total_display":"323,891.07","total_whole":"323,891","shares_owned_after":144897.0,"shares_owned_after_display":"144,897","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-04","filed_date":"2021-05-05","scope":"insider"},{"id":4892332,"accession":"0001209191-21-030491","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-030491","line_url":"/filing/0001209191-21-030491#line-5","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1279.0,"shares_display":"1,279","price_per_share":24.4691,"price_display":"24.47","price_state":"stated","total_value":31295.9789,"total_display":"31,295.98","total_whole":"31,296","shares_owned_after":143618.0,"shares_owned_after_display":"143,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-04","filed_date":"2021-05-05","scope":"insider"},{"id":4892319,"accession":"0001209191-21-030491","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-030491","line_url":"/filing/0001209191-21-030491#line-3","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10661.0,"shares_display":"10,661","price_per_share":24.4578,"price_display":"24.46","price_state":"stated","total_value":260744.6058,"total_display":"260,744.61","total_whole":"260,745","shares_owned_after":147957.0,"shares_owned_after_display":"147,957","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-05","scope":"insider"},{"id":4892315,"accession":"0001209191-21-030491","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-030491","line_url":"/filing/0001209191-21-030491#line-2","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4339.0,"shares_display":"4,339","price_per_share":24.9075,"price_display":"24.91","price_state":"stated","total_value":108073.6425,"total_display":"108,073.64","total_whole":"108,074","shares_owned_after":143618.0,"shares_owned_after_display":"143,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-05","scope":"insider"},{"id":6046791,"accession":"0001209191-18-037311","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-037311","line_url":"/filing/0001209191-18-037311#line-2","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4900.0,"shares_display":"4,900","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":98000.0,"total_display":"98,000.00","total_whole":"98,000","shares_owned_after":77636.0,"shares_owned_after_display":"77,636","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-12","filed_date":"2018-06-12","scope":"insider"},{"id":6046787,"accession":"0001209191-18-037311","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-037311","line_url":"/filing/0001209191-18-037311#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":2000.0,"total_display":"2,000.00","total_whole":"2,000","shares_owned_after":82536.0,"shares_owned_after_display":"82,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-11","filed_date":"2018-06-12","scope":"insider"},{"id":6801866,"accession":"0001209191-18-031804","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-031804","line_url":"/filing/0001209191-18-031804#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":200000.0,"total_display":"200,000.00","total_whole":"200,000","shares_owned_after":82636.0,"shares_owned_after_display":"82,636","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-18","filed_date":"2018-05-21","scope":"insider"},{"id":2601463,"accession":"0001209191-16-147288","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-147288","line_url":"/filing/0001209191-16-147288#line-2","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3912.0,"shares_display":"3,912","price_per_share":21.83,"price_display":"21.83","price_state":"stated","total_value":85398.96,"total_display":"85,398.96","total_whole":"85,399","shares_owned_after":75957.0,"shares_owned_after_display":"75,957","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-26","filed_date":"2016-10-28","scope":"insider"},{"id":2786704,"accession":"0001209191-16-143056","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-143056","line_url":"/filing/0001209191-16-143056#line-2","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1841.0,"shares_display":"1,841","price_per_share":24.66,"price_display":"24.66","price_state":"stated","total_value":45399.06,"total_display":"45,399.06","total_whole":"45,399","shares_owned_after":75957.0,"shares_owned_after_display":"75,957","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-28","filed_date":"2016-09-28","scope":"insider"},{"id":2211397,"accession":"0001209191-16-138944","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-138944","line_url":"/filing/0001209191-16-138944#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654337","owner_name":"Ali-Jackson Kamil","owner_display_name":"Ali-Jackson Kamil","owner_url":"/insider/0001654337","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3738.0,"shares_display":"3,738","price_per_share":20.35,"price_display":"20.35","price_state":"stated","total_value":76068.3,"total_display":"76,068.30","total_whole":"76,068","shares_owned_after":20289.0,"shares_owned_after_display":"20,289","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-26","filed_date":"2016-08-29","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":26,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":25,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":26},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001034842","name":"RIGEL PHARMACEUTICALS INC","url":"/issuer/0001034842","role":"Director","n_filings":2,"first_seen":"2026-05-28","last_seen":"2026-06-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001472091","name":"PDS Biotechnology Corp","url":"/issuer/0001472091","role":"Director","n_filings":1,"first_seen":"2021-06-17","last_seen":"2021-06-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001557746","name":"Aclaris Therapeutics, Inc.","url":"/issuer/0001557746","role":"Officer (Chief Legal Officer)","n_filings":9,"first_seen":"2016-08-29","last_seen":"2021-06-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001654337","retrieved_at":"2026-08-22T04:54:24+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}